#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15410	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2114	725.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1708	1708	T	867	T	798	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15410	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2114	725.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1442	1442	C	922	C	849	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28502	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3472	817.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1678	1678	A	947	A,G	869,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28502	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3472	817.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2312	2312	C	936	C,T	850,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28502	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3472	817.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2386	2386	A	921	A	865	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28502	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3472	817.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2938	2938	C	832	C,G	787,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	2198	folP	852	852	99.88	folP.l15.c4.ctg.1	1567	139.6	0	.	p	.	0	A204V	NONSYN	610	612	GCA	957	959	GTA	215;214;211	G;T;A	200;203;200	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	2198	folP	852	852	99.88	folP.l15.c4.ctg.1	1567	139.6	1	SNP	p	R228S	0	.	.	682	684	CGC	1029	1031	CGC	202;204;202	C,A;G;C	183,1;185;182	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5886	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3282	178.7	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1007	1009	ATA	199;198;197	A;T;A	189;186;185	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5886	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3282	178.7	0	.	p	.	0	V893I	NONSYN	2677	2679	GTT	2936	2938	ATT	203;199;197	A,G;T;T	181,1;179;177	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5886	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3282	178.7	1	SNP	p	S91F	0	.	.	271	273	TCC	530	532	TCC	210;209;209	T;C;C	195;196;196	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5886	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3282	178.7	1	SNP	p	D95G	0	.	.	283	285	GAC	542	544	GAC	195;196;193	G;A;C	182;179;178	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5886	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3282	178.7	1	SNP	p	D95N	0	.	.	283	285	GAC	542	544	GAC	195;196;193	G;A;C	182;179;178	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1798	mtrR	633	633	99.37	mtrR.l15.c30.ctg.1	1425	126.0	0	.	p	.	0	A39T	NONSYN	115	117	GCC	485	487	ACC	221;223;222	A;C;C	202;210;209	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1798	mtrR	633	633	99.37	mtrR.l15.c30.ctg.1	1425	126.0	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	683	685	CAC	255;251;248	C;A,T;C	235;231,1;232	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1798	mtrR	633	633	99.37	mtrR.l15.c30.ctg.1	1425	126.0	1	SNP	p	G45D	0	.	.	133	135	GGC	503	505	GGC	229;231;233	G;G;C	211;213;213	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	962	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1071	89.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5496	parC	2304	2304	99.74	parC.l6.c30.ctg.1	2995	182.9	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1611	1613	GCC	216;217;216	G;C;C	195;199;196	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5496	parC	2304	2304	99.74	parC.l6.c30.ctg.1	2995	182.9	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1653	1655	GCA	216;214;215	G;C,A;A	194;187,1;190	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5496	parC	2304	2304	99.74	parC.l6.c30.ctg.1	2995	182.9	1	SNP	p	D86N	0	.	.	256	258	GAC	606	608	GAC	215;217;219	G;A;C	192;190;194	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5496	parC	2304	2304	99.74	parC.l6.c30.ctg.1	2995	182.9	1	SNP	p	S87I	0	.	.	259	261	AGT	609	611	AGT	216;215;218	A;G;T	190;191;194	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5496	parC	2304	2304	99.74	parC.l6.c30.ctg.1	2995	182.9	1	SNP	p	S87R	0	.	.	259	261	AGT	609	611	AGT	216;215;218	A;G;T	190;191;194	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5496	parC	2304	2304	99.74	parC.l6.c30.ctg.1	2995	182.9	1	SNP	p	S87W	0	.	.	259	261	AGT	609	611	AGT	216;215;218	A;G;T	190;191;194	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5496	parC	2304	2304	99.74	parC.l6.c30.ctg.1	2995	182.9	1	SNP	p	S88P	0	.	.	262	264	TCC	612	614	TCC	217;215;216	T;C;C	192;189;192	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4658	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2667	174.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1572	1574	GGC	196;193;192	G;G;C	179;179;178	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.14.001	penA.14.001	1	1	27	4394	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2341	186.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1290	1292	GCA	260;262;268	G;C;A	241;242;246	penA.14.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	27	4394	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2341	186.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1293	1295	ATC	269;272;276	A;T;C	248;248;249	penA.14.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	27	4394	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2341	186.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1305	1307	GTG	265;263;265	G;T;G	248;244;246	penA.14.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	27	4394	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2341	186.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1305	1307	GTG	265;263;265	G;T;G	248;244;246	penA.14.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	27	4394	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2341	186.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1809	1811	ACC	212;212;211	A;C;C,A	191;200;199,1	penA.14.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	27	4394	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2341	186.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1863	1865	GCG	191;190;191	G;C,G;G	173;156,1;166	penA.14.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	27	4394	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2341	186.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1863	1865	GCG	191;190;191	G;C,G;G	173;156,1;166	penA.14.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	27	4394	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2341	186.9	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1986	1988	GGT	165;167;163	G;G;T	145;148;149	penA.14.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	27	4394	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2341	186.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1995	1997	GGC	156;156;155	G;G;C	146;143;142	penA.14.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.14.001	penA.14.001	1	1	27	4394	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2341	186.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2013	2015	CCG	139;142;139	C,CGG;C;G,C	106,1;108;107,1	penA.14.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6244	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3077	202.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2468	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1799	136.5	0	.	p	.	0	S22G	NONSYN	64	66	AGC	426	428	GGC	161;159;161	G;G;C	142;143;143	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2468	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1799	136.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	608	608	C	200	C	179	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	T18M	NONSYN	52	54	ACG	352	354	ATG	207;203;202	A;T;G	185;181;179	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	D41K	NONSYN	121	123	GAC	421	423	AAA	212;211;213	A;A;A	195;196;194	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	K46S	NONSYN	136	138	AAA	436	438	AGC	220;218;220	A;G;C	201;198;199	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	A82V	NONSYN	244	246	GCC	544	546	GTC	206;204;207	G;T;C	180;172;178	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	T89S	NONSYN	265	267	ACC	565	567	AGC	211;209;208	A;G;C	188;186;184	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	A109T	NONSYN	325	327	GCC	625	627	ACC	176;178;182	A,G;C;C	160,1;167;169	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	691	693	TAT	216;215;215	T;A;T	197;199;196	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	N134E	NONSYN	400	402	AAT	700	702	GAG	218;218;220	G;A;G	198;198;201	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	V135F	NONSYN	403	405	GTG	703	705	TTT	221;224;223	T;T;T	198;203;206	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	G140K	NONSYN	418	420	GGA	718	720	AAA	239;237;242	A;A;A	218;216;220	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	727	729	CAA	242;246;245	C,G;A;A	216,1;217;217	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	859	861	CGA	224;221;219	C;G;A	206;203;200	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	S189N	NONSYN	565	567	AGC	865	867	AAC	226;232;231	A;A;C	211;212;208	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	H213P	NONSYN	637	639	CAT	937	939	CCT	226;231;232	C;C;T	213;217;216	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	V215F	NONSYN	643	645	GTT	943	945	TTT	239;239;240	T;T;T	225;228;229	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	0	.	p	.	0	R258K	NONSYN	772	774	AGG	1072	1074	AAG	263;264;265	A,C;A,G;G,T	247,1;248,1;243,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2736	porB1b	1047	1047	96.75	porB1b.l15.c4.ctg.1	1486	183.0	1	SNP	p	G120K	0	.	.	358	360	GGC	658	660	GGC	188;186;192	G;G;C	174;174;178	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11094	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	4965	223.0	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2034	2036	CAT	238;240;236	C;A;T	217;215;211	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1208	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	981	122.2	1	SNP	p	V57M	1	.	.	169	171	ATG	483	485	ATG	250;252;255	A;T;G	229;232;235	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
tetM.WHO_G_pTetM_00047	tetM.WHO_G_pTetM_00047	1	0	27	17710	tetM	1920	1920	100.0	tetM.l15.c30.ctg.1	2612	676.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Tetracycline resistance
